BPC-157 vs TB-500
BPC-157 and TB-500 are among the most widely studied tissue-repair peptides in preclinical research. Both appear in overlapping research contexts, including connective tissue injury, recovery, and angiogenesis, but their mechanisms are fundamentally different. BPC-157 is a partial sequence of the gastric Body Protection Compound, acting primarily through nitric oxide pathways and growth factor modulation. TB-500 is a synthetic analog of the Thymosin Beta-4 actin-binding region, regulating cell migration via G-actin sequestration. Researchers studying tissue-repair mechanisms frequently compare these compounds to understand which biological pathways are most relevant to their experimental model.
BPC-157
Pentadecapeptide (15 amino acids)
TB-500
Synthetic Tβ4 fragment (17 amino acids)
At a Glance
Key research profiles for each compound.
BPC-157
Gastric pentadecapeptide studied for cytoprotection and tissue repair
Class
Pentadecapeptide (15 amino acids)
Mechanism
Nitric oxide pathway, growth factor upregulation
Half-Life
Rapid clearance, under 4 hours in preclinical models
Research Area
Gut health, connective tissue, neuroprotection
- Investigated for tendon and ligament repair in preclinical models
- Studied for gastric cytoprotection and gut-brain axis modulation
- Documented role in angiogenesis and nitric oxide pathway signaling
- Examined for CNS neuroprotective properties in rodent models
TB-500
Thymosin Beta-4 fragment studied for cellular migration and recovery
Class
Synthetic Tβ4 fragment (17 amino acids)
Mechanism
Actin sequestration, G-actin binding, ADS motif
Half-Life
Estimated 6 to 8 hours in preclinical models
Research Area
Musculoskeletal repair, cardiovascular, inflammation
- Studied for actin-sequestering activity and cellular migration in vitro
- Investigated for angiogenesis promotion and vascular repair in models
- Examined for anti-inflammatory properties in tissue injury models
- Explored for cardiac and musculoskeletal repair mechanisms
Side-by-Side Comparison
Key research parameters compared directly.
| Feature | BPC-157 | TB-500 |
|---|---|---|
| Peptide Class | Pentadecapeptide (15 AA) | Tβ4 fragment (17 AA) |
| Primary Mechanism | NO pathway, growth factor upregulation | Actin sequestration, G-actin binding |
| Research Area | Gut, tendon, CNS, angiogenesis | Muscle, cardiac, vascular, inflammation |
| Molecular Weight | ~1,419 Da | ~2,112 Da |
| Estimated Half-Life | Under 4 hours (preclinical) | 6 to 8 hours (preclinical) |
| Source Derivation | Gastric juice BPC partial sequence | Thymosin Beta-4 ADS motif region |
| Systemic vs Local | Both systemic and local effects in models | Documented systemic distribution in models |
| Stack Compatibility | Frequently researched with TB-500 | Frequently researched with BPC-157 |
Research Deep-Dive
BPC-157
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide representing a partial sequence of the human gastric BPC protein. In preclinical models, BPC-157 has been studied extensively for its cytoprotective properties across the gastrointestinal tract, with documented interactions with the nitric oxide synthesis pathway and upregulation of growth factors including VEGF and EGF receptor signaling. Research in rodent models has examined tendon and ligament repair, CNS neuroprotection following traumatic injury, and modulation of the gut-brain axis. Its stability in gastric acid and documented effects at low concentrations make it a frequent subject of gastroenterological research.
View BPC-157 →TB-500
TB-500 is a synthetic analog of the ADS (actin-binding) region of Thymosin Beta-4, an endogenous actin-sequestering protein that regulates actin polymerization dynamics in virtually all cell types. In vitro, TB-500 binds G-actin, reducing the pool of monomeric actin available for filament formation. This mechanism is tied to cell migration, wound healing, and angiogenesis signaling. Preclinical models have examined TB-500 in contexts including cardiac repair following ischemic injury, musculoskeletal recovery, and anti-inflammatory signaling. Its longer estimated half-life relative to BPC-157 and documented systemic distribution following administration have made it a subject of comparative pharmacokinetic research.
View TB-500 →Research Context
In preclinical research, BPC-157 and TB-500 are frequently studied in parallel or as a combination model. The Wolverine Stack, Spartan's combined BPC-157/TB-500 product, reflects the common research design of examining both compounds simultaneously. Researchers studying connective tissue repair typically choose BPC-157 for gut or CNS models and TB-500 for muscle or cardiovascular models, though both exhibit angiogenic properties and show overlap in tendon repair contexts.
Frequently Asked Questions
Research Use Cases
Research Stacks
Source Both Compounds
BPC-157 and TB-500 are both available from Spartan Peptides at ≥98% HPLC-verified purity. Domestic US supply, same-day dispatch before 2 PM. All products for in-vitro research use only.
All compounds are strictly for in-vitro research use only and not intended for human consumption.